Targeted Therapies
By Laura Morgan
This article highlights the new therapies targeting a specific biomarker that have become available for patients with non–small-cell lung cancer in the past 3 years, significantly improving patient survival. Read More ›
Sometimes we hear words that sound familiar but we don’t fully know their meaning. This article explains the common terms “personalized medicine” and “targeted therapy” used by oncologists, and why we need to understand them. Read More ›
On September 15, 2021, the FDA approved Exkivity (mobocertinib) capsules, an oral kinase inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed during or after platinum-based chemotherapy, a cancer with few treatment options. Read More ›
People with triple-negative breast cancer (TNBC) that has spread to other parts of the body (metastatic) now have a new treatment option called Trodelvy (sacituzumab govitecan-hziy). This drug was recently approved by the Food and Drug Administration (FDA) for use specifically in adult patients with metastatic TNBC who have already received at least 2 previous treatments for their cancer. Read More ›
By Chase Doyle
One biomarker that is involved in lung cancer is the ALK mutations. Although several drugs are now available for this type of lung cancer, new evidence shows that some patients may need different therapies. Read More ›
By Chase Doyle
Just because a cancer drug is approved by the FDA does not mean its therapeutic benefit is completely understood. Improving outcomes and minimizing side effects of a drug often requires using the drug in different doses or in combination with other drugs. Read More ›
By Dan Dean
Until recently, the initial treatment for patients with CLL was chemotherapy alone. New targeted therapies are now available for use as the first treatment for CLL. At the 2019 ASCO meeting, 2 experts discussed the benefits of these new treatments. Read More ›
By Dana Taylor
New findings show that starting with a targeted therapy regimen instead of chemotherapy improves outcomes for patients with chronic lymphocytic leukemia, particularly for those under age 70. Read More ›
Targeted therapies for lung cancer are newer therapies designed to target specific types of genetic mutations found in some patients, and improve the response to treatment. Read More ›